{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:27:52Z","timestamp":1767144472108,"version":"build-2238731810"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005753","name":"Kungliga Fysiografiska S\u00e4llskapet i Lund","doi-asserted-by":"publisher","award":["20151111"],"award-info":[{"award-number":["20151111"]}],"id":[{"id":"10.13039\/501100005753","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Per-Eric och Ulla Schybergs stiftelse","award":["20160413"],"award-info":[{"award-number":["20160413"]}]},{"name":"Ollie and Elof Ericssons Stiftelse","award":["20150907"],"award-info":[{"award-number":["20150907"]}]},{"name":"Stiftelsen Thelma Zo\u00e9gas","award":["V2016\/925"],"award-info":[{"award-number":["V2016\/925"]}]},{"DOI":"10.13039\/501100003173","name":"the Crafoord Foundation","doi-asserted-by":"crossref","award":["20160643"],"award-info":[{"award-number":["20160643"]}],"id":[{"id":"10.13039\/501100003173","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006350","name":"Stiftelsen Clas Groschinskys Minnesfond","doi-asserted-by":"publisher","award":["M16 29"],"award-info":[{"award-number":["M16 29"]}],"id":[{"id":"10.13039\/501100006350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Swedish Childhood Cancer Foundation","doi-asserted-by":"crossref","award":["PR2014-0059"],"award-info":[{"award-number":["PR2014-0059"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006313","name":"Swedish Childhood Cancer Foundation","doi-asserted-by":"crossref","award":["TJ2014-0047"],"award-info":[{"award-number":["TJ2014-0047"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.canlet.2017.01.035","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T21:46:02Z","timestamp":1485985562000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["The dual specificity PI3K\/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)"],"prefix":"10.1016","volume":"392","author":[{"given":"Mohiuddin","family":"Gazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sausan A.","family":"Moharram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Marh\u00e4ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0719-5336","authenticated-orcid":false,"given":"Julhash U.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2017.01.035_bib1","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2017.01.035_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13045-016-0344-4","article-title":"Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K\/AKT\/mTOR signaling pathway","volume":"9","author":"Lonetti","year":"2016","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.canlet.2017.01.035_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2011.08957.x","article-title":"T-cell acute lymphoblastic leukaemia: recent molecular biology findings","volume":"156","author":"Kraszewska","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2017.01.035_bib4","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.canlet.2017.01.035_bib5","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1172\/JCI34616","article-title":"PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability","volume":"118","author":"Silva","year":"2008","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.canlet.2017.01.035_bib6","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","article-title":"Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance","volume":"13","author":"Rozengurt","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2017.01.035_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","article-title":"Regulation of mTORC1 by PI3K signaling","volume":"25","author":"Dibble","year":"2015","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2017.01.035_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/1078-0432.CCR-15-0114","article-title":"Modulation of glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia by increasing BIM expression with the PI3K\/mTOR inhibitor BEZ235","volume":"22","author":"Hall","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.01.035_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fonc.2014.00108","article-title":"Targeting the PI3K\/mTOR pathway in pediatric hematologic malignancies","volume":"4","author":"Tasian","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2017.01.035_bib10","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.canlet.2017.01.035_bib11","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-10-1694","article-title":"Antitumor efficacy of PKI-587, a highly potent dual PI3K\/mTOR kinase inhibitor","volume":"17","author":"Mallon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2017.01.035_bib12","doi-asserted-by":"crossref","first-page":"57770","DOI":"10.18632\/oncotarget.10760","article-title":"Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling","volume":"7","author":"Moharram","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2017.01.035_bib13","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1182\/blood-2010-11-318873","article-title":"The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia","volume":"118","author":"Gutierrez","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2017.01.035_bib14","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2009-07-235143","article-title":"Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia","volume":"115","author":"Sanda","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2017.01.035_bib15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood-2006-12-059790","article-title":"Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"110","author":"Winter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2017.01.035_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbamcr.2015.08.015","article-title":"Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting","volume":"1863","author":"Chiarini","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2017.01.035_bib17","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1073\/pnas.0506200103","article-title":"Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment","volume":"103","author":"Indraccolo","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2017.01.035_bib18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nchembio817","article-title":"Systems biology and combination therapy in the quest for clinical efficacy","volume":"2","author":"Fitzgerald","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2017.01.035_bib19","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/bjc.2014.241","article-title":"The dual PI3K\/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models","volume":"110","author":"D'Amato","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2017.01.035_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jss.2011.10.045","article-title":"PKI-587 and sorafenib targeting PI3K\/AKT\/mTOR and Ras\/Raf\/MAPK pathways synergistically inhibit HCC cell proliferation","volume":"176","author":"Gedaly","year":"2012","journal-title":"J.\u00a0Surg. Res."},{"key":"10.1016\/j.canlet.2017.01.035_bib21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1636","article-title":"Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia","volume":"13","author":"Palomero","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2017.01.035_bib22","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1016\/j.canlet.2019.05.012","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000}}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517300770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517300770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:37:35Z","timestamp":1759592255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383517300770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":22,"alternative-id":["S0304383517300770"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2017.01.035","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dual specificity PI3K\/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2017.01.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}